Carna Biosciences Profit Margin

The latest profit margin for CBIXF is -295.59% as of June 2026. That compares with -374.02% in the prior-year period — up 21.0% year over year. That is below the Healthcare sector average of 9.71%. Investors often review this figure alongside Carna Biosciences's historical trend and sector peers before judging valuation or financial health.

Over the past year, CBIXF's profit margin moved from -374.02% to -295.59% — a 21.0% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Carna Biosciences's valuation or profitability profile.

Against Healthcare companies, CBIXF currently prints -295.59% for profit margin, while the sector average sits near 9.71%. That is roughly 3145.5% below the sector mean. Large gaps often invite a closer look at Carna Biosciences's growth, margins, and balance sheet.

Profit Margin shows how effectively Carna Biosciences converts resources into returns. At -295.59%, CBIXF may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -374.02% in the prior-year period — up 21.0% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting CBIXF's profit margin (-295.59%), review year-over-year change from -374.02%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.